Fetal Therapy for Twin Anemia-Polycythemia Sequence

Twin anemia-polycythemia sequence (TAPS) is a severe complication of monochorionic twin pregnancy. It develops when very small placental vascular connections allow a slow, unbalanced transfer of blood from one fetus to the other. The donor twin becomes anemic, while the recipient twin develops polycythemia, or an abnormally high concentration of red blood cells.

Unlike twin-to-twin transfusion syndrome, TAPS usually occurs without a major difference in amniotic fluid volume. That feature can make recognition more difficult, especially when ultrasound surveillance is infrequent or the condition develops after treatment for another placental disorder. Careful Doppler assessment and coordinated fetal medicine expertise are therefore essential.

Treatment decisions depend on gestational age, disease stage, fetal condition, placental anatomy, and the experience of the treating center. Options range from close surveillance to intrauterine transfusion, fetoscopic laser surgery, early delivery, or combinations of these approaches. The aim is to protect both fetuses while allowing pregnancy to continue safely whenever possible.

Recognizing The Placental Imbalance

TAPS is caused by tiny, usually less than 1 millimeter, arteriovenous connections within a shared placenta. Blood passes gradually from the donor circulation into the recipient circulation. Because the exchange is slow, the pregnancy may not show the dramatic fluid imbalance, bladder changes, or abdominal enlargement associated with classic twin-to-twin transfusion syndrome.

The donor twin may develop reduced oxygen-carrying capacity, increased cardiac workload, and signs of fetal compromise. The recipient twin faces increased blood viscosity, cardiac strain, and possible organ injury. Severe cases can lead to hydrops fetalis, neurological damage, or fetal death, although the clinical course varies considerably.

Doppler ultrasound is central to screening. The middle cerebral artery peak systolic velocity, commonly abbreviated MCA-PSV, helps estimate fetal anemia or polycythemia. A raised MCA-PSV in the donor and a low value in the recipient create the characteristic pattern. Researchers and clinicians also use the intertwin MCA-PSV difference, fetal growth, fluid volume, placental appearance, and signs of cardiac dysfunction to refine the assessment.

Confirming Diagnosis And Severity

A diagnosis should be based on the full fetal picture rather than a single Doppler measurement. The sonographer evaluates both twins, records amniotic fluid and bladder findings, examines umbilical and venous blood flow, and looks for cardiomegaly, ventricular dysfunction, hydrops, or abnormal placental circulation. Serial examinations are especially important because TAPS can progress over a short period.

Antenatal staging systems classify disease according to Doppler abnormalities and evidence of fetal deterioration. Lower stages may have abnormal MCA values without obvious clinical compromise. Higher stages include critical Doppler changes, cardiac dysfunction, hydrops, or the death of one or both fetuses. The stage, rate of progression, and gestational age help determine whether intervention should be immediate or carefully deferred.

Fetal anemia can sometimes be confirmed or treated through cordocentesis, in which blood is sampled from the umbilical cord. This invasive procedure carries risks, including bleeding, infection, membrane rupture, and fetal loss. It is generally reserved for situations in which the result will change management or transfusion is required.

Choosing A Fetal Treatment Pathway

Management should be discussed by a multidisciplinary team that includes maternal-fetal medicine specialists, fetal surgeons, ultrasound experts, neonatologists, anesthesiologists, and transfusion professionals. Parents need a clear explanation of expected benefits, procedural risks, uncertainty about neurological outcome, and the possibility that treatment may save one fetus but not both.

Expectant management can be appropriate for mild, stable disease, particularly when pregnancy is already advanced and fetal testing remains reassuring. Surveillance may include ultrasound one or more times each week, Doppler velocimetry, cardiotocography when appropriate, and assessment for maternal symptoms or early labor. A low threshold for reassessment is important because Doppler findings can change quickly.

Intrauterine transfusion may correct donor anemia, but it does not remove the abnormal placental connections. The recipient twin may continue to receive excess red cells, so transfusion can function as a temporary measure or as part of a broader strategy. Selective reduction is rarely considered and involves profound ethical and technical issues. Delivery may be the safest option when the fetuses are sufficiently mature or when intrauterine therapy is unlikely to provide benefit.

How Fetoscopic Laser Therapy Works

Fetoscopic laser surgery targets the placental vessels responsible for the unbalanced transfusion. Under ultrasound guidance, a small fetoscope is introduced through the maternal abdomen and uterus into the amniotic cavity. The surgeon maps the vascular equator between the twins and uses laser energy to close communicating vessels.

The goal is to separate the circulations so that each fetus has an independent placental territory. Some specialists use a Solomon-type technique, in which a laser line is drawn along the vascular equator after individual connections are treated. This may reduce the chance of residual microscopic connections, although the choice of technique depends on placental anatomy, gestational age, and operator expertise.

Laser therapy has potential advantages because it addresses the underlying cause rather than only replacing blood or postponing delivery. It also has important risks, including preterm premature rupture of membranes, preterm birth, placental bleeding, infection, fetal loss, and neurological injury. A procedure can technically succeed while one fetus remains compromised because damage may have occurred before treatment.

Following fetoscopy, the fluid volume, cervical length, fetal heart activity, Doppler readings, and signs of membrane complications are monitored closely. The pregnancy may require hospitalization or frequent specialist review. Antenatal corticosteroids are often considered when preterm birth is plausible, while the timing and use of other medications are individualized.

Monitoring The Fetus After Treatment

Post-treatment surveillance is designed to detect residual disease, recurrent transfusion, anemia, hydrops, growth restriction, and complications of prematurity. MCA Doppler values may be difficult to interpret immediately after intervention, especially if blood has been redistributed or transfusion has occurred. Trends over time are usually more informative than an isolated measurement.

The neurological outlook depends on the severity and duration of anemia, polycythemia, hypoxia, hemodynamic instability, and prematurity. Brain ultrasound and, when clinically indicated, fetal or neonatal magnetic resonance imaging may contribute to risk assessment. Families should receive balanced counseling: normal findings are reassuring, but they cannot eliminate every developmental concern.

The neonatal team should be involved before birth, particularly when delivery is expected at an early gestation or when either twin has cardiac dysfunction or hydrops. Newborns may require respiratory support, hematocrit assessment, treatment for anemia or hyperviscosity, glucose monitoring, and evaluation for neurological complications. Broader perinatal screening principles, including pulse oximetry screening, can also support the routine assessment of vulnerable newborns after stabilization.

Supporting Newborns And Families

The effects of TAPS extend beyond the fetal procedure. Parents may experience prolonged uncertainty, emergency decisions, grief related to a loss, or anxiety about the health of a surviving twin. Counseling should be continuous rather than limited to the consent discussion. Clear communication between the fetal therapy unit, referring obstetric team, and neonatal service reduces conflicting information.

After birth, nutrition and developmental follow-up become part of long-term care. Human milk can be particularly valuable for premature or medically fragile infants, although feeding plans must reflect respiratory status, gastrointestinal function, and the mother’s recovery. Information about human milk bank support may help families and clinicians plan for situations in which expressed maternal milk is temporarily unavailable.

Procedural and intensive care experiences can also expose newborns to repeated painful interventions. Neonatal teams should use validated pain assessment, skin-to-skin contact when safe, facilitated tucking, non-nutritive sucking, sucrose where appropriate, and carefully selected analgesic medication. Evidence-based neonatal pain care is part of comprehensive recovery, not an optional addition to technical treatment.

Practical Priorities For Care Teams

A high-quality pathway combines early recognition, rapid referral, technically appropriate intervention, and long-term follow-up. Because TAPS can emerge after an apparently uncomplicated scan or after treatment for twin-to-twin transfusion syndrome, care plans should specify who reviews Doppler results and how families can access urgent assessment.

Important priorities include:

• Screen monochorionic twin pregnancies with regular ultrasound and MCA Doppler surveillance.
• Refer suspected TAPS promptly to a center with fetal therapy and neonatal intensive care expertise.
• Interpret Doppler findings alongside fluid volume, growth, cardiac function, and clinical stage.
• Discuss surveillance, transfusion, laser surgery, and delivery as changing options rather than fixed choices.
• Arrange neonatal, neurological, developmental, nutritional, and psychosocial follow-up before discharge.

Research continues to refine diagnostic thresholds, staging systems, laser techniques, and methods for predicting neurological outcome. Prospective registries and collaboration between fetal medicine and neonatal networks are particularly valuable because TAPS is less common than other complications of monochorionic twins. Shared data can help clarify which pregnancies benefit most from intervention and when treatment should occur.

Care should remain individualized. A fetus with severe anemia at 24 weeks presents a different problem from a stable pregnancy at 32 weeks, and placental anatomy may make one procedure safer than another. Families deserve timely information in understandable language, access to specialist review, and a plan that is revisited whenever ultrasound findings change.

When TAPS is suspected, prompt referral can preserve treatment options and improve coordination before an emergency develops. Fetal medicine teams, obstetricians, sonographers, neonatologists, and families should work together from diagnosis through birth and childhood follow-up, making each decision around the condition of both twins and the safety of the pregnancy.